Copy to clipboard 
CrossRoads Extremity Systems acquired a range of FDA-cleared technology assets from Surgical Frontiers. The add-on acquisition furthers CrossRoads’ strategy to grow its presence in the orthopedic extremities sector. Transaction details were not disclosed.
- The KATOR® family of soft tissue-to-bone reattachment products for Achilles tendon repair, ligament stabilization, and arthroscopic rotator cuff repair
- OsteoPrecise™ precision cutting guides for bone alignment in small bone osteotomies and fusions
- The SpeedButton™ for anatomic ligament reattachment with strong pull-out strength and a better ligament footprint
- The Metrics portfolio for the precise, reproducible restoration of anatomic bone alignment and ligament function in high ankle sprains and ankle fractures
The acquired assets are covered by a total of 16 issued and 10 pending U.S. patents. These products were developed under the umbrella of Surgical Frontiers, which collaborates on the development of clinically-ready technologies for sale to exiting medical device companies for their commercialization.
CrossRoads is a Fund IV portfolio company of private equity firm HealthpointCapital, which invested in CrossRoads Extremity Systems in 2019. CrossRoads’ Active Stabilization® technology supports fusion through continuous dynamic compression and enhances stability through a hybrid construct of a nitinol staple within a fixation plate. Further, the company’s reusable instrumentation and EcoSMART® instrument recovery program promote efficient inventory management and improved economics for healthcare facilities.
“As we continue on our fast-growth trajectory, we are excited to add to our portfolio a range of technologies that have significant advantages over the current standard of care,” said Vernon Hartdegen, CEO and Co-Founder of CrossRoads. “These unique and highly complementary technologies and intellectual property will further round out our product portfolio and drive cross-selling opportunities. The acquisition is perfectly aligned with our philosophy of offering less-invasive surgical solutions centered on better outcomes for the patient and ease of use for the surgeon.”
CrossRoads Extremity Systems acquired a range of FDA-cleared technology assets from Surgical Frontiers. The add-on acquisition furthers CrossRoads' strategy to grow its presence in the orthopedic extremities sector. Transaction details were not disclosed.
The KATOR® family of soft tissue-to-bone reattachment...
CrossRoads Extremity Systems acquired a range of FDA-cleared technology assets from Surgical Frontiers. The add-on acquisition furthers CrossRoads’ strategy to grow its presence in the orthopedic extremities sector. Transaction details were not disclosed.
- The KATOR® family of soft tissue-to-bone reattachment products for Achilles tendon repair, ligament stabilization, and arthroscopic rotator cuff repair
- OsteoPrecise™ precision cutting guides for bone alignment in small bone osteotomies and fusions
- The SpeedButton™ for anatomic ligament reattachment with strong pull-out strength and a better ligament footprint
- The Metrics portfolio for the precise, reproducible restoration of anatomic bone alignment and ligament function in high ankle sprains and ankle fractures
The acquired assets are covered by a total of 16 issued and 10 pending U.S. patents. These products were developed under the umbrella of Surgical Frontiers, which collaborates on the development of clinically-ready technologies for sale to exiting medical device companies for their commercialization.
CrossRoads is a Fund IV portfolio company of private equity firm HealthpointCapital, which invested in CrossRoads Extremity Systems in 2019. CrossRoads’ Active Stabilization® technology supports fusion through continuous dynamic compression and enhances stability through a hybrid construct of a nitinol staple within a fixation plate. Further, the company’s reusable instrumentation and EcoSMART® instrument recovery program promote efficient inventory management and improved economics for healthcare facilities.
“As we continue on our fast-growth trajectory, we are excited to add to our portfolio a range of technologies that have significant advantages over the current standard of care,” said Vernon Hartdegen, CEO and Co-Founder of CrossRoads. “These unique and highly complementary technologies and intellectual property will further round out our product portfolio and drive cross-selling opportunities. The acquisition is perfectly aligned with our philosophy of offering less-invasive surgical solutions centered on better outcomes for the patient and ease of use for the surgeon.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
